Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).
D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000880:Anthraquinones / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D013280:Stomatitis / Q000139:chemically induced; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D014750:Vincristine; D011239:Prednisolone; D008727:Methotrexate